Comparative Pharmacology
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
GENOSYL vs NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
1-2 drops of ophthalmic solution (neomycin 3.5 mg/mL and dexamethasone 1 mg/mL) or ointment (neomycin 3.5 mg/g and dexamethasone 1 mg/g) into the affected eye(s) every 4-6 hours; in severe cases, every 1-2 hours initially and tapered. For otic use: 3-4 drops into the affected ear(s) 3-4 times daily. Topical: apply thin layer to affected area 1-3 times daily.
None Documented
None Documented
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Neomycin: 2-3 h (topical/ophthalmic absorption minimal; if significant, prolonged in renal impairment). Dexamethasone: 4-6 h (ophthalmic, systemic if absorbed).
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Renal: neomycin ~30-80% unchanged; dexamethasone phosphate ~80% as free/free glucuronide metabolites. Fecal: negligible.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic